|
May 24
|
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
|
|
May 14
|
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy
|
|
Apr 22
|
Celularity Inc. to Host Investor and Analyst Research & Development Day
|
|
Apr 19
|
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
|
|
Apr 18
|
Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024
|
|
Apr 15
|
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products
|
|
Apr 8
|
Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells
|
|
Mar 26
|
Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L
|
|
Mar 20
|
Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy
|
|
Mar 14
|
Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE Summit
|
|
Mar 12
|
Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress
|
|
Mar 7
|
Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells
|
|
Jan 25
|
Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions
|
|
Aug 29
|
Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron
|
|
May 1
|
Celularity Announces Acceptance of Presentation at 26th Annual Meeting of the American Society of Gene and Cell Therapy
|
|
Apr 27
|
Celularity Announces Clinical Data on Human Placental-Derived Unmodified Allogeneic Natural Killer Cell Therapy Candidate Cynk-001 in Adult Patients With Relapsed Refractory and Measurable Residual Disease-Positive Acute Myeloid Leukemia
|